Stock Track | INNOVENT BIO Soars 6.05% in Morning Trading on Strong Earnings and First Annual Profit

Stock Track03-27

INNOVENT BIO's stock surged 6.05% during morning trading, reflecting strong investor confidence following the release of the company's annual financial results.

The company reported total revenue of RMB 13.0415 billion, representing a year-on-year increase of 38.4%. Notably, INNOVENT BIO achieved its first full-year profit, with IFRS net profit reaching RMB 814 million, a significant turnaround from a loss of RMB 94.63 million in the previous year.

Product revenue, a key driver of growth, rose 44.6% year-on-year to RMB 11.896 billion, bolstered by the company's leading position in oncology and the rapid expansion of its product portfolio. Non-IFRS net profit also saw a dramatic increase of 419.6% to RMB 1.723 billion, further underscoring the company's enhanced profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment